Restart Life Sciences Corp.
HEAL
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 96.80K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 96.80K | -- | -- | -- | -- |
| Cost of Revenue | 52.20K | -- | -- | -- | -- |
| Gross Profit | 44.50K | -- | -- | -- | -- |
| SG&A Expenses | 261.60K | 221.30K | 121.50K | 112.80K | 461.70K |
| Depreciation & Amortization | 2.90K | 300.00 | 300.00 | 300.00 | 300.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 320.30K | 221.60K | 121.90K | 113.10K | 465.50K |
| Operating Income | -223.60K | -221.60K | -121.90K | -113.10K | -465.50K |
| Income Before Tax | -234.50K | -112.80K | -153.20K | -147.10K | -570.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -234.50K | -112.80K | -153.20K | -147.10K | -570.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -234.50K | -112.80K | -153.20K | -147.10K | -570.50K |
| EBIT | -223.60K | -221.60K | -121.90K | -113.10K | -465.50K |
| EBITDA | -222.60K | -221.30K | -121.50K | -112.80K | -465.10K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 56.51M | 39.29M | 35.89M | 33.59M | 26.73M |
| Average Diluted Shares Outstanding | 56.51M | 39.29M | 35.89M | 33.59M | 26.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |